ClinicalTrials.gg
CompletedNCT05541939Updated Jun 25, 2024Results posted

Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects

A Phase 2 interventional study of Mizagliflozin in Postbariatric Hypoglycemia, sponsored by Vogenx, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-25.

Sponsored by Vogenx, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 294 studies in Hypoglycemia with a site in United States — 36 open to participants now, 49 under way, 5 of them phase 3. Hypoglycemia · United States.

Enrollment
193rd of 239
9 · median 24
Started
2022
with 11 others
Phase 2
38 of 294
3 open now
Registered
246th of 294
by date

Among the 294 studies in Hypoglycemia with a site in United States, this one is the 193rd largest by enrollment of the 239 interventional ones that give a count, is one of 12 that started in 2022, is one of 38 in phase 2, and was the 246th registered.

Hypoglycemia

706 studies on the registry are indexed under Hypoglycemia; 94 are open to participants now.

Browse Hypoglycemia studies →

Open to participants now

36 of the 294 studies in Hypoglycemia with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 36 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 59 Hypoglycemia studies recruiting now, 23 (39%) set no upper age limit and 31 (53%) stop at 75 or younger; 18 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 294 studies in Hypoglycemia with a site in United States, or all of them as a file.
02

Study summary

This clinical study will examine the safety and tolerability, as well as the effects of orally administered mizagliflozin on post prandial glucose and insulin levels in subjects diagnosed with post-bariatric hypoglycemia (PBH).

Read the detailed description

This is a Phase 2 randomized, sequential crossover single ascending dose study in PBH subjects to determine the effect of two mizagliflozin formulations This study will examine single doses of mizagliflozin in either a liquid or encapsulated formulation. Subjects will be randomly assigned to one of two treatment arms. Safety, tolerability and pharmacodynamic response to mizagliflozin will be assessed in subjects during a mixed meal tolerance test (MMTT).

03

Conditions studied

  • Postbariatric Hypoglycemia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Roux-en-Y gastric bypass surgery performed > 6 months prior to enrollment
  • Diagnosis of PBH

Exclusion criteria

Exclusion Criteria:

  • History of current medical conditions (other than PBH) which may result in hypoglycemia such as insulinoma, adrenal insufficiency, insulin hypoglycemia, congenital hyperinsulinemia.
  • Current use of insulin or insulin secretagogues.
  • History of current dumping syndrome.
  • History of current fasting hypoglycemia.
  • Pregnancy and/ or Lactation: For women of : there is a requirement for a negative urine pregnancy test and for agreement to use during the study and for at least 2 weeks after participating in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Treatment Arm A

    Subjects will receive two separate single doses (Period 1 and Period 2) of encapsulated mizagliflozin

    Drug: Mizagliflozin

  • Experimental
    Treatment Arm B

    Subjects will receive one dose of liquid formulation (Period 1), and one dose (optional) of encapsulated mizagliflozin (Period 2)

    Drug: Mizagliflozin

Interventions

06

What researchers measure

Primary outcomes

  1. Glucose Nadir After Mizagliflozin Dosing

    Time course of glucose concentrations during MMTT

    Time frame: 0-3 hours following liquid meal

07

Results

Posted Jun 25, 2024

Participant flow

9 participants were screened between September 2022 and January 2023. 7 participants at University of Colorado/Anschutz Medical Campus and 2 participants at Stanford.University

Participant flow — Overall Study
MilestoneTreatment Arm ATreatment Arm B
Started54
Completed54
Not completed00

Outcome measures

PrimaryGlucose Nadir After Mizagliflozin Dosing

Time course of glucose concentrations during MMTT

Time frame:
0-3 hours following liquid meal
Reported as:
Mean · mg/dL
Glucose Nadir After Mizagliflozin Dosing
mg/dLTreatment Arm ATreatment Arm B
2.5 mg Capsule6.2 ± 14.8—
5.0 mg Capsule4.0 ± 17.7—
2.5 mg Liquid—17.5 ± 30.5
10.0 mg Capsule—31.5 ± 29.0

Adverse events

Collected over 34 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment Arm A Period 1 (2.5 mg Capsule)0/5 (0%)0/5 (0%)4/5 (80%)
Treatment Arm A Period 2 (5.0 mg Capsule)0/5 (0%)0/5 (0%)1/5 (20%)
Treatment Arm B Period 1 (2.5 mg Liquid Formulation)0/4 (0%)0/4 (0%)2/4 (50%)
Treatment Arm B Period 2 (10.0 mg Capsule)0/4 (0%)0/4 (0%)2/4 (50%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventTreatment Arm A Period 1 (2.5 mg Capsule)Treatment Arm A Period 2 (5.0 mg Capsule)Treatment Arm B Period 1 (2.5 mg Liquid Formulation)Treatment Arm B Period 2 (10.0 mg Capsule)
AnemiaBlood and lymphatic system disorders2/50/51/40/4
NauseaGastrointestinal disorders2/50/51/41/4
HypokalaemiaMetabolism and nutrition disorders2/50/50/40/4
LeukopeniaBlood and lymphatic system disorders0/50/51/40/4
Abdominal distensionGastrointestinal disorders1/50/50/41/4
DiarrhoeaGastrointestinal disorders0/50/51/41/4
HungerGeneral disorders0/50/51/40/4
HeadacheNervous system disorders1/50/51/40/4
VomitingGastrointestinal disorders1/50/50/40/4
Infections and infestationsGeneral disorders0/51/50/40/4

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment Arm ATreatment Arm BTotal
<=18 years000
Between 18 and 65 years448
>=65 years101
Sex: Female, Male
Sex: Female, Male(Participants)Treatment Arm ATreatment Arm BTotal
Female538
Male011
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment Arm ATreatment Arm BTotal
Hispanic or Latino123
Not Hispanic or Latino426
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment Arm ATreatment Arm BTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White437
More than one race000
Unknown or Not Reported000
Baseline MMTT (pharmacodynamic assessment for glucose and insulin)
Baseline MMTT (pharmacodynamic assessment for glucose and insulin)(Participants)Treatment Arm ATreatment Arm BTotal
Count of participants549
08

Study locations

2 sites
  • Stanford
    Palo Alto, California 94304, United States
  • University of Colorado / Anschutz Medical Campus
    Aurora, Colorado 80045, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Feb 2023, 5 months.

Results were first posted in Jun 2024, 1 year 4 months after primary completion.

Of 24 phase 2 interventional studies under Hypoglycemia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 31. This study's 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2022
First posted
Sep 15, 2022
StartActual
Sep 13, 2022
Primary completionActual
Feb 17, 2023
CompletionActual
Feb 17, 2023
Results first posted
Jun 25, 2024
Last update
Jun 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05541939
Lead sponsor
Vogenx, Inc.
Responsible party
Sponsor
First posted
Sep 15, 2022
Start date
Sep 13, 2022
Primary completion
Feb 17, 2023
Completion
Feb 17, 2023
Results posted
Jun 25, 2024
Last update
Jun 25, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mizagliflozin

Start the discussion